Direct costs will be estimated for each of the four treatment strategies. Door-to-reperfusion times and mortality will be available at the patient level, which will allow for the calculation of averages as well as variability estimates for analysis of uncertainty. Average cost and effectiveness (time-to-reperfusion interval and life years)

will be calculated and if one treatment strategy is found to be superior Inhibitors,research,lifescience,medical (i.e. cost savings with survival benefits), and then these results will be reported in a cost consequence format. If the superior strategy is found to involve cost and outcome trade-offs (i.e. cost increasing with survival benefits), then incremental cost-effectiveness, as measured through additional cost per reduction in time-to-reperfusion interval and additional cost per life year gained, will be calculated. A Priori Subgroup Analysis • Rural vs. urban settings and academic vs non academic Inhibitors,research,lifescience,medical destination hospitals • Geographical bias subgroup analysis comparing all non PCI capable sites for distance from PCI site; Ethical Considerations and Human Subjects Protection PREDICT is an observational, prospective non-interventional study based on review of routinely collected source data and as such meets

the requirements for minimal risk research[38-40]. Inhibitors,research,lifescience,medical Approval by 47 research ethics boards/committees covering 71 hospitals will be sought to launch the study. MGCD0103 mw Discussion There is a lack of a comprehensive dataset for Acute Coronary Syndrome (ACS) patients, which includes the prehospital component of care[3]. We anticipate that this study will bridge this gap, providing valuable information on processes of

care and the benefits of different prehospital treatment strategies. We have planned to address four threats to protocol compliance and internal Inhibitors,research,lifescience,medical validity; 1) ethics approval Inhibitors,research,lifescience,medical and privacy requirements from 47 research ethics boards/committees covering 71 hospitals, 2) temporal bias of comparison induced by delays to implementation across sites, 3) data guardian training and oversight of timeliness and quality, and 4) technological advances that may outpace the study and affect recruitment. This trial involves rural and urban centres and this means that many research ethics boards will need to review this protocol and our request for waiver of consent. We anticipate that rural and small community hospitals will struggle with the request for waiver of consent and the privacy Suplatast tosilate issues associated with chart abstraction, acquisition of personal information enabling telephone follow up at 30 days and at one year. Our strategy will be to obtain approval from all the academic centres first and enclose a copy of their approval with submission to the smaller centres. In addition we have established a data sharing agreement template that has the approval of the administration and legal advisors of the 18 academic and community hospitals in our largest metropolitan area.